Improving and addressing lymphocytes response against SARS-CoV-2 and its variants with intralveolar BCG administration

Bacillus Calmette Guerin administered by the aerosol route may locally elicit and increase T1 lymphocyte response in pulmonary alveoli, which are the main target of SARS-2-CoV-2 and its variants, thus preventing and anticipating the virus attack. This may lead to a decrease of the most severe forms of the disease considered as an acute autoimmune virus inducted disease. The lymphocyte response may start to work before and regardless of anti-CoVid vaccination.